Identifying Exercise-Induced Bronchospasm

Hermansen, Christian L.; Kirchner, Jeffrey T.

doi:10.3810/psm.2005.12.271

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[131] recently reported a multicenter, double-blinded, active-control, randomized trial (MOSAIC) to compare the efficacy of oral MON and inhaled fluticasone in children 6 to 14 years old with mild persistent asthma. The non-inferiority MOSAIC clinical trial is one of the first long-term (12 months of treatment) and large (n=994) studies comparing the relative benefit of an oral LTRA (MON) and an IC (fluticasone) in asthma control in children.…”

Section: Bronchial Asthmamentioning

confidence: 99%

“…Cys-LTs have been implicated in the pathogenesis of exerciseinduced airway obstruction. An increase in LTE 4 has been observed after exercise in adults and in children with severe asthma [129][130][131], although neither the pre-exercise LTE 4 nor the rise in LTE 4 after exercise correlated with the degree of exercise-induced bronchoconstriction (EIB) [132][133][134].…”

Section: Exercise Induced Asthmamentioning

confidence: 99%

See 1 more Smart Citation

Antileukotriene Drugs: Clinical Application, Effectiveness and Safety

Riccioni¹,

Bucciarelli²,

Mancini³

et al. 2007

CMC

114

102

View full text Add to dashboard Cite

Cysteinyl leukotrienes (Cys-LTs) are potent proinflammatory mediators derived from arachidonic acid through the 5-lypoxigenase (5-LO) pathway. They exert important pharmacological effects by interaction with at least two different receptors: Cys-LT(1) and Cys-LT(2). By competitive binding to the Cys-LT(1) receptor, leukotriene receptor antagonist drugs such as montelukast, zafirlukast, and pranlukast, block the effects of Cys-LTs and alleviate the symptoms of many chronic diseases, especially bronchial asthma and allergic rhinitis. Evidence obtained by randomized clinical trials as also by direct experience derived from patients suffering from asthma and allergic rhinitis justifies a broader role for leukotrienes receptor antagonists (LTRAs). Recently published studies and case reports have demonstrated beneficial effects of LTRAs on other diseases commonly associated with asthma (exercise induced asthma, rhinitis, chronic obstructive pulmonary disease, interstitial lung disease, chronic urticaria, atopic dermatitis, allergic fungal disease, nasal polyposis, and paranasal sinus disease) as well as other diseases not connected to asthma (migraine, respiratory syncytial virus postbronchiolitis, systemic mastocytosis, cystic fibrosis, pancreatitis, vulvovaginal candidiasis, cancer, atherosclerosis, eosinophils cystitis, otitis media, capsular contracture, and eosinophilic gastrointestinal disorders). The aim of this review is to show the most recent applications and effectiveness in clinical practice of the LTRAs.

show abstract

Section: Bronchial Asthmamentioning

confidence: 99%